Search

Displaying results 3331 - 3340 of 5895 in total
  1. Drug

    Dimetindene

    go.drugbank.com/drugs/DB08801
    ApprovedInvestigational

    Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.

  2. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials. … [L15361] A convenient feature of Bayer's formulation is the ability to divide the scored tablets manually without the need for pill-cutting devices.[L15361]

  3. Drug

    Lopinavir

    go.drugbank.com/drugs/DB01601
    ApprovedInvestigational

    Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. … [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's

  4. Drug

    Lecithin, soybean

    go.drugbank.com/drugs/DB14161
    Investigational

    A complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed as 1,2-diacyl-3-phosphocholine...

    Mixtures: Protect Plus SO 60
  5. Drug

    Quinapril

    go.drugbank.com/drugs/DB00881
    ApprovedInvestigational

    [L8420,L8423] It is used to treat hypertension and heart failure.

    Mixtures: QUINAPRIL E IDROCLOROTIAZIDE MYLAN GENERICS, QUINAPRIL E IDROCLOROTIAZIDE MYLAN GENERICSProducts: QUINAPRIL MYLAN GENERICS
  6. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.

  7. Drug

    Lifitegrast

    go.drugbank.com/drugs/DB11611
    ApprovedInvestigational

    It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].

  8. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    [A198807] Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19.

  9. Drug

    Bordetella pertussis fimbriae 2/3 antigen

    go.drugbank.com/drugs/DB10790
    ApprovedInvestigational

    Bordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct

  10. Drug

    Copper Cu-64

    go.drugbank.com/drugs/DB13980
    Approved

    Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.